[IgE-κ type multiple myeloma achieving complete response with novel agents]

Area of Science:

• Hematology
• Oncology

Background:

• IgE multiple myeloma (MM) is a rare subtype with a typically poor prognosis.
• Novel agents have improved outcomes in general MM, but data for IgE MM are limited.

Observation:

• A case of IgE-kappa MM in a 53-year-old male presenting with rib pain.

Findings:

• The patient received upfront multidrug chemotherapy including bortezomib and lenalidomide, followed by autologous stem-cell transplantation (ASCT).
• Complete response was achieved after subsequent treatment with pomalidomide.
• Previous reports indicate poor prognosis for refractory IgE MM treated with novel agents, contrasting with this patient's outcome.

Implications:

• Early use of novel agents and ASCT may significantly improve long-term survival in IgE MM.
• This case suggests a potential therapeutic strategy for improving outcomes in this rare MM subtype.